Who is sponsoring NCT02990481?

NCT02990481 is sponsored by Toray Industries, Inc.

What drugs are being tested in NCT02990481?

Interventions in NCT02990481: TRK-950, TRK-950, TRK-950.

What condition does NCT02990481 study?

NCT02990481 studies Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma.

Is NCT02990481 still recruiting?

NCT02990481 is currently completed. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT02990481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Completed Phase 1 Last updated 16 April 2025

What this trial tests

Phase 1 trial testing TRK-950 in Locally Advanced or Metastatic Solid Carcinomas in 38 participants. Completed in 16 September 2019.

Timeline

6 March 2017

Primary endpoint
16 September 2019

16 September 2019

Quick facts

Lead sponsor	Toray Industries, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	6 March 2017
Primary completion	16 September 2019
Estimated completion	16 September 2019
Sites	3 locations across France, United States

Drugs / interventions tested

TRK-950 — full drug profile →
TRK-950 — full drug profile →
TRK-950 — full drug profile →

Conditions studied

Locally Advanced or Metastatic Solid Carcinomas — all drugs for Locally Advanced or Metastatic Solid Carcinomas →
Colon Cancer — all drugs for Colon Cancer →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →

Sponsor

Toray Industries, Inc — full company profile →

Who can join

18 and older, any sex, with Locally Advanced or Metastatic Solid Carcinomas or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Systemic treatment options for advanced biliary tract carcinoma.
Xie C, McGrath NA, Monge Bonilla C, Fu J. · · 2020 · cited 17× · PMID 32748173 · DOI 10.1007/s00535-020-01712-9
Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950.
Okano F, Saito T, Minamida Y, Kobayashi S, et al · · 2023 · cited 10× · PMID 37082579 · DOI 10.1158/2767-9764.crc-22-0310
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond.
Yamamoto K, Nakayama I, Shitara K. · · 2025 · cited 2× · PMID 40535734 · DOI 10.1177/17588359251344804
Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors.
Cassier PA, Borad MJ, Sharma S, Dubois B, et al · · 2025 · cited 1× · PMID 40557916 · DOI 10.1158/2767-9764.crc-25-0123

Verify or expand the search:

Other trials of TRK-950

Trials testing the same drug.

NCT06038578 — A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer · Phase 2 · recruiting

Other Toray Industries, Inc trials

Trials by the same sponsor.

NCT06038578 — A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer · Phase 2 · recruiting
NCT04804943 — Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome) · NA · recruiting
NCT03727802 — Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis · Phase 1 · completed
NCT03346330 — Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750 · Phase 1 · completed
NCT03043248 — TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02990481 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Toray Industries, Inc
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02990481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing